Sees FY25 adjusted operating expenses $230M-$240M. The company projects its total net revenue can reach at least $700M by 2028, a compound annual growth rate of 27% from 2024, based on the combination of its existing aesthetic neurotoxin business and anticipated launch of the Evolysse and Estyme injectable HA gels beginning in 2025. Evolus (EOLS) expects to achieve non-GAAP operating income margins of at least 20% by 2028 by leveraging its highly synergistic, existing infrastructure.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EOLS:
- EOLS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Evolus: Strategic Developments and FDA Approvals Drive Buy Rating with Promising Growth Projections
- Evolus Gains ‘Buy’ Rating: FDA Approval and Unique Technology Drive Growth Potential
- Evolus Gains Buy Rating on Early FDA Approval and Strategic Market Positioning
- Evolus’s Strategic Advancements and Early FDA Approval Boost Growth Potential